期刊
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
卷 279, 期 7, 页码 3685-3694出版社
SPRINGER
DOI: 10.1007/s00405-021-07229-y
关键词
Sarcopenia; Head and neck cancer; Body composition; Skeletal muscle mass; Chemoradiotherapy; Image-based analysis
This study investigates the predictive value of skeletal muscle mass (SMM) for cisplatin dose-limiting toxicities (DLT) in patients with locally advanced head and neck cancer (LA-HNC). The results show that low SMM is associated with an increased risk of DLT and suggest the need for further trials to consider SMM in cisplatin dosing.
Purpose Evidence suggests that patients' skeletal muscle mass (SMM) can predict the patients at risk for cisplatin dose-limiting toxicities (DLT). Cisplatin is currently dosed on body surface area (BSA). The predictive value of SMM for cisplatin DLT in patients with locally advanced head and neck cancer (LA-HNC) is investigated. Methods Patients with LA-HNC treated with cisplatin-based chemoradiotherapy (CRT) were included. SMM was measured using pre-treatment scans. Logistic regression analysis was performed to identify the predictive impact of low SMM for DLT. Results In total, 343 patients were included of which 199 patients (58.0%) had low SMM and 154 patients (44.9%) experienced cisplatin DLT. In multivariate analysis, low SMM at diagnosis was the only predictive factor for DLT (HR 1.8, 95% CI 1.1-2.9). Conclusions Low SMM was associated with an increased risk of DLT. Trials are needed to investigate cisplatin dosing with consideration of SMM rather than solely BSA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据